LONDON & NEW YORK–(BUSINESS WIRE)–Eleusis, a clinical stage life science company established to develop the therapeutic potential of psychedelics, today announced the publication of its sponsored preclinical research in the American Chemical Society’s journal Chemical Neuroscience, which suggests that psychedelics may have more persistent antidepressant therapeutic efficacy than ketamine. The study also indicates that the antidepressant effect of psychedelics are both biological and context-dependent, and the subjective existential experience or “mystical experience” often associated with psychedelics may be correlated with, but not cause, the persisting antidepressant effect. The publication, titled “Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a...
[Source: stocksnewsfeed.com] [ Comments ] [See why this is trending]